Microarchitecture, but Not Bone Mechanical Properties, Is Rescued with Growth Hormone Treatment in a Mouse Model of Growth Hormone Deficiency

Table 1

Vertebral and femoral tissue mineral density (TMD) and bone macrostructure including cross-sectional area (CSA) and cortical thickness (Ct.Th) in GH-sufficient (GHS), GH-deficient (GHD), early treatment (early; daily GH injections from age 21 to 60 days), late treatment (late; daily GH injections from age 35 to 60 days), and saline control (saline; daily saline injections from age 21 to 60 days). Mean and standard errors are reported, and the coefficient of variation (CV%). *𝑃≤0.05, **𝑃≤0.001 versus GHS, ⁺𝑃≤0.05, ⁺⁺𝑃≤0.001 versus GHD, ^#𝑃≤0.05 versus early.

(a)

Group	Vertebra body height (mm)	Vertebra Body CSA (mm^2)	Vertebra TMD (mgHA/ccm)
GHS	3.19±0.040	1.82±0.030	829.8±10.1
GHD	2.28±0.041 **	1.17±0.016 **	819.5±9.0
Early	2.72±0.026^**++	1.39±0.021^**++	840.0±3.0
Late	2.69±0.042^**++	1.43±0.043^**++	821.0±6.9
Saline	2.26±0.063	1.18±0.036	832.7±5.8
CV%	4.9%	6.2%	2.6%

(b)

Group	Femur length; (mm)	Femur CSA; (mm^2)	Medullary CSA; (mm^2)	Femur Ct.Th; (mm)	Femur TMD; (mgHA/ccm)
GHS	14.97±0.10	2.092±0.063	1.111±0.035	0.224±0.005	897.9±16.8
GHD	11.29±0.07 **	1.190±0.020 **	0.679±0.015 **	0.150±0.002 **	888.3±12.8
Early	12.72±0.08^**++	1.421±0.030^**+	0.752±0.017 **	0.184±0.004^**++	909.9±5.6
Late	12.37±0.08^**++#	1.429±0.046^**+	0.786±0.024^**+	0.176±0.005^**++	905.9±6.3
Saline	11.32±0.04	1.218±0.039	0.702±0.029	0.150±0.004	898.8±5.9
CV%	1.8%	7.9%	8.8%	6.4%	3.3%